Combining kinase biology with precision oncology, Kinnate raises $75M series B

Aiming to develop precision cancer therapies that can treat more patients, Kinnate emerged from stealth Thursday with $74.5 million in an untranched series B from new investors OrbiMed Advisors, Nextech Invest and Vida Ventures.

Foresite Capital and Eshelman Ventures also invested in the financing. Foresite led Kinnate’s $22 million series A in April 2018, with participation from Eshelman...